ArticleEuropean journal of pediatrics2026
Safety profiles of calcineurin inhibitor-related infections in the pediatric population: a real-world pharmacovigilance analysis.
Article in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to assess infection-related adverse events (AEs) associated with calcineurin inhibitors (CNIs), including cyclosporine (CsA) and tacrolimus (TAC), in the pediatric population using combined postmarketing surveillance databases. Data from the FDA Adverse Event Reporting System (FAERS) and the Japanese Adverse Drug Event Report (JADER) were analyzed for pediatric patients. Disproportionality analysis was conducted to evaluate AEs. Additionally, subgroup analysis, fatal outcome assessment, and time-to-onset (TTO) analysis were also performed. A total of 426 CsA-related and 1284 TAC-related infection reports were identified in FAERS, with corresponding findings in JADER (CsA, n = 140; TAC, n = 323). Cross-database analysis identified positive overlapping signals for BK virus, cytomegalovirus, and Epstein-Barr virus infections for both drugs. Age- and sex-stratified analysis revealed differences in infection-related reporting patterns, with the percentage of fatal outcomes varying significantly across age groups and being highest in the youngest subgroups: 3-5 years for CsA (29.2%) and 0-2 years for TAC (18.4%) (P < 0.05).
conclusionThis study provides real-world evidence on infection-related safety signals associated with CNIs in pediatric patients, particularly for viral infections. The distinct signal profiles and age- and sex-specific patterns highlight the importance of individualized infection risk monitoring and immunosuppressive management strategies. WHAT IS KNOWN: • Calcineurin inhibitors (CNIs), including cyclosporine (CsA) and tacrolimus (TAC), are widely used in pediatric transplantation and immune-mediated diseases, but infection remains an important safety concern during CNI-based immunosuppression. • Evidence on the comparative infection-related safety profiles of these two agents in children remains limited. WHAT IS NEW: • This is the first dual-database pharmacovigilance analysis to characterize infection-related safety signals associated with CsA and TAC in pediatric patients. • Age- and sex-specific patterns were identified, with fatal outcomes significantly associated with younger age groups for both drugs.
Indexed as
Identifiers
42760444What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.